Artificial intelligence (AI) software developer Imbio has garnered U.S. Food and Drug Administration (FDA) 510(k) clearance for RV/LV Analysis, a cardiothoracic imaging AI algorithm.
Designed to provide automated assessment of potential right ventricular dilation, RV/LV Analysis calculates the ratio of the maximum diameter of the right versus the left ventricle of the heart on CT pulmonary angiography exams, according to the vendor. This RV/LV ratio is a patient risk indicator for various pulmonary conditions, including pulmonary embolism, Imbio said.
The company said that the software's results are automatically available for clinicians; a full report of quantitative findings is added to the patient's imaging study within minutes.
![Images show the pectoralis muscles of a healthy male individual who never smoked (age, 66 years; height, 178 cm; body mass index [BMI, calculated as weight in kilograms divided by height in meters squared], 28.4; number of cigarette pack-years, 0; forced expiratory volume in 1 second [FEV1], 97.6% predicted; FEV1: forced vital capacity [FVC] ratio, 0.71; pectoralis muscle area [PMA], 59.4 cm2; pectoralis muscle volume [PMV], 764 cm3) and a male individual with a smoking history and chronic obstructive pulmonary disorder (COPD) (age, 66 years; height, 178 cm; BMI, 27.5; number of cigarette pack-years, 43.2, FEV1, 48% predicted; FEV1:FVC, 0.56; PMA, 35 cm2; PMV, 480.8 cm3) from the Canadian Cohort Obstructive Lung Disease (i.e., CanCOLD) study. The CT image is shown in the axial plane. The PMV is automatically extracted using the developed deep learning model and overlayed onto the lungs for visual clarity.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/03/genkin.25LqljVF0y.jpg?auto=format%2Ccompress&crop=focalpoint&dpr=2&fit=crop&h=167&q=70&w=250)
